Sugi Predict

Sugi Predict / Compounds / SCHEMBL23748301

SCHEMBL23748301

SCHEMBL23748301

Cc1ccc2nc(N(C)C)c(/C=[N+](\[O-])Cc3ccccc3)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 4/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ PSMB5 P28074 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ GFER P55789 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ PDE10A Q9Y233 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748308 0.83 MAPT (0.54) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL23748306 0.82 GAA (0.46) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL23748239 0.81 KMT2A (0.43) KDM4EGAAMAPTNPSR1RXFP1
SCHEMBL23748255 0.77 MAPT (0.41) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL23748325 0.72 PTGS2 (0.47) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL23748238 0.71 MAPT (0.38) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL11971613 0.70 ALDH1A1 (0.79) KDM4EGAAALDH1A1PSMB5SMN1; SMN2
SCHEMBL23748305 0.70 MAPT (0.39) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL23748312 0.69 MAPT (0.46) KDM4EGAAALDH1A1MAPTNPSR1
SCHEMBL23748276 0.69 ALDH1A1 (0.42) KDM4EGAAALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12102631-B2 Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2024-10-01 — — US disclosed
EP-3863632-B1 QUINOLYLNITRONE FOR USE IN THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA ISQUAEMIA BIOTECH S L (ES) 2023-06-07 — — EP disclosed
US-20210330662-A1 QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA ISQUAEMIA BIOTECH, S.L. (ES) 2021-10-28 — — US disclosed
EP-3863632-A1 QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA Isquaemia Biotech, S.L. (ES) 2021-08-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12102631-B2 Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia NLN, TXN2, TXN KDM4E 4281/4885GAA 222/4885ALDH1A1 1297/4885
US-20210330662-A1 QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA NLN, TXN2, TXN KDM4E 4281/4885GAA 222/4885ALDH1A1 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.